An IRGD Peptide Conjugated Heparin Nanocarrier for Gastric Cancer Therapy

Overview

Journal RSC Adv

Publisher Royal Society of Chemistry

Specialty Chemistry

Date 2022 May 13

PMID 35547284

Authors

Shichao Ai

Shuang Zhen

Zhijian Liu

Feng Sun

Xingchen He

Feng Chu

Wenxian Guan

Jianquan Wang

Affiliations

Soon will be listed here.

Abstract

The -diamminedichloroplatinum(ii) (DDP, cisplatin) is an important antitumor drug for the therapy of gastric cancer in clinics, but it is limited by its nonspecific tissue distribution and severe side effects. Here, an integrin targeted drug delivery system iRGD-heparin nanocarrier (iHP) was successfully synthesized. The iHP has several unique properties. First, this nanocarrier has excellent biodegradation due to its heparin biopolymer frame. Second, it is biocompatible because succinic anhydride-modified heparin has no anticoagulant activity and cell toxicity. We proved that from anticoagulant function evaluation and a cytotoxicity test. Third, iRGD was conjugated to the nanoparticles as an integrin-targeting ligand. Our results showed that iHP has precise targeting to integrin-overexpressed human gastric cancer cells MKN-45P and tumor tissues . Hence, we synthesized targeted nanoparticles iHP-DDP (iHDDP) and untargeted nanoparticles HP-DDP (HDDP). In our result, iHDDP showed higher antitumor efficacy than HDDP and . And in comparison with free DDP, the iHDDP nanoparticle delivery system showed satisfactory antitumor activity of DDP without weight loss or liver and kidney damage in nude mice bearing MKN-45P tumors.

Citing Articles

Opportunities and Challenges of Nanoparticles in Digestive Tumours as Anti-Angiogenic Therapies.

Yang Z, Deng W, Zhang X, An Y, Liu Y, Yao H Front Oncol. 2022; 11:789330.

PMID: 35083147 PMC: 8784389. DOI: 10.3389/fonc.2021.789330.

References

Nie S . Understanding and overcoming major barriers in cancer nanomedicine. Nanomedicine (Lond). 2010; 5(4):523-8. PMC: 2913868. DOI: 10.2217/nnm.10.23. View

Guven A, Rusakova I, Lewis M, Wilson L . Cisplatin@US-tube carbon nanocapsules for enhanced chemotherapeutic delivery. Biomaterials. 2011; 33(5):1455-61. PMC: 3417041. DOI: 10.1016/j.biomaterials.2011.10.060. View

Danhier F, Le Breton A, Preat V . RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. Mol Pharm. 2012; 9(11):2961-73. DOI: 10.1021/mp3002733. View

Lazarevic T, Rilak A, Bugarcic Z . Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives. Eur J Med Chem. 2017; 142:8-31. DOI: 10.1016/j.ejmech.2017.04.007. View

Inoue Y, Shimazawa M, Nakamura S, Takata S, Hashimoto Y, Izawa H . Both Autocrine Signaling and Paracrine Signaling of HB-EGF Enhance Ocular Neovascularization. Arterioscler Thromb Vasc Biol. 2017; 38(1):174-185. DOI: 10.1161/ATVBAHA.117.310337. View

Liu Y, Tan J, Thomas A, Ou-Yang D, Muzykantov V . The shape of things to come: importance of design in nanotechnology for drug delivery. Ther Deliv. 2012; 3(2):181-94. PMC: 3408634. DOI: 10.4155/tde.11.156. View

Arosio D, Casagrande C . Advancement in integrin facilitated drug delivery. Adv Drug Deliv Rev. 2015; 97:111-43. DOI: 10.1016/j.addr.2015.12.001. View

Desgrosellier J, Cheresh D . Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2009; 10(1):9-22. PMC: 4383089. DOI: 10.1038/nrc2748. View

Teesalu T, Sugahara K, Kotamraju V, Ruoslahti E . C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc Natl Acad Sci U S A. 2009; 106(38):16157-62. PMC: 2752543. DOI: 10.1073/pnas.0908201106. View

10.

Knop K, Hoogenboom R, Fischer D, Schubert U . Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem Int Ed Engl. 2010; 49(36):6288-308. DOI: 10.1002/anie.200902672. View

11.

Lee S, Xie J, Chen X . Peptides and peptide hormones for molecular imaging and disease diagnosis. Chem Rev. 2010; 110(5):3087-111. PMC: 2868934. DOI: 10.1021/cr900361p. View

12.

Wang J, Lee G, Lu Q, Peng X, Wu J, Wu S . Quantitative Examination of the Active Targeting Effect: The Key Factor for Maximal Tumor Accumulation and Retention of Short-Circulated Biopolymeric Nanocarriers. Bioconjug Chem. 2017; 28(5):1351-1355. DOI: 10.1021/acs.bioconjchem.7b00138. View

13.

Lu J, Chuan X, Zhang H, Dai W, Wang X, Wang X . Free paclitaxel loaded PEGylated-paclitaxel nanoparticles: preparation and comparison with other paclitaxel systems in vitro and in vivo. Int J Pharm. 2014; 471(1-2):525-35. DOI: 10.1016/j.ijpharm.2014.05.032. View

14.

Gunawardhana N, Jang S, Choi Y, Hong Y, Jeon Y, Kim A . -Induced HB-EGF Upregulates Gastrin Expression via the EGF Receptor, C-Raf, Mek1, and Erk2 in the MAPK Pathway. Front Cell Infect Microbiol. 2018; 7:541. PMC: 5775237. DOI: 10.3389/fcimb.2017.00541. View

15.

Uhland K . Matriptase and its putative role in cancer. Cell Mol Life Sci. 2006; 63(24):2968-78. PMC: 11136049. DOI: 10.1007/s00018-006-6298-x. View

16.

Yang X, Du H, Liu J, Zhai G . Advanced nanocarriers based on heparin and its derivatives for cancer management. Biomacromolecules. 2014; 16(2):423-36. DOI: 10.1021/bm501532e. View

17.

Assaraf Y, Leamon C, Reddy J . The folate receptor as a rational therapeutic target for personalized cancer treatment. Drug Resist Updat. 2014; 17(4-6):89-95. DOI: 10.1016/j.drup.2014.10.002. View

18.

Sugahara K, Teesalu T, Karmali P, Kotamraju V, Agemy L, Greenwald D . Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science. 2010; 328(5981):1031-5. PMC: 2881692. DOI: 10.1126/science.1183057. View

19.

Bhirde A, Patel V, Gavard J, Zhang G, Sousa A, Masedunskas A . Targeted killing of cancer cells in vivo and in vitro with EGF-directed carbon nanotube-based drug delivery. ACS Nano. 2009; 3(2):307-16. PMC: 2665730. DOI: 10.1021/nn800551s. View

20.

Stathopoulos G, Boulikas T, Vougiouka M, Deliconstantinos G, Rigatos S, Darli E . Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study. Oncol Rep. 2005; 13(4):589-95. View